Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange

Ras mutations are the oncogenic drivers of many human cancers and yet there are still no approved Ras-targeted cancer therapies. Inhibition of Ras nucleotide exchange is a promising new approach but better understanding of this mechanism of action is needed. Here we describe an antibody mimetic, DARPin K27, which inhibits nucleotide exchange of Ras. K27 binds preferentially to the inactive Ras GDP form with a Kd of 4 nM and structural studies support its selectivity for inactive Ras. Intracellular expression of K27 significantly reduces the amount of active Ras, inhibits downstream signalling, in particular the levels of phosphorylated ERK, and slows the growth in soft agar of HCT116 cells. K27 is a potent, non-covalent inhibitor of nucleotide exchange, showing consistent effects across different isoforms of Ras, including wild-type and oncogenic mutant forms.

[1]  Roger L. Williams,et al.  Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS , 2007, The EMBO journal.

[2]  J. Griffiths,et al.  Absolute Quantification of Endogenous Ras Isoform Abundance , 2015, PloS one.

[3]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[4]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[5]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[6]  Mohammad Reza Ahmadian,et al.  Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras , 1997, Nature Structural Biology.

[7]  A. Plückthun,et al.  Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[9]  Norbert Perrimon,et al.  Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices , 2015, Proceedings of the National Academy of Sciences.

[10]  Kenji Shimizu,et al.  Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change , 1982, Nature.

[11]  Yi Liu,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[12]  Paramjit S. Arora,et al.  An Orthosteric Inhibitor of the Ras-Sos Interaction , 2011, Nature chemical biology.

[13]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[14]  S. Biocca,et al.  Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex. , 2001, European journal of biochemistry.

[15]  D. Esposito,et al.  Dragging ras back in the ring. , 2014, Cancer cell.

[16]  John Kuriyan,et al.  The structural basis of the activation of Ras by Sos , 1998, Nature.

[17]  T. Rabbitts,et al.  Interfering with RAS–effector protein interactions prevent RAS-dependent tumour initiation and causes stop–start control of cancer growth , 2010, Oncogene.

[18]  R. Minter,et al.  Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy , 2016, Oncotarget.

[19]  T. Rabbitts,et al.  Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation , 2003, The EMBO journal.

[20]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[21]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[22]  M. Barbacid,et al.  T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes , 1982, Nature.

[23]  S H Kim,et al.  Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. , 1992, Science.

[24]  A. Plückthun,et al.  Designed ankyrin repeat proteins (DARPins) as novel isoform-specific intracellular inhibitors of c-Jun N-terminal kinases. , 2012, ACS chemical biology.

[25]  Yong Zhou,et al.  Ras nanoclusters: Versatile lipid-based signaling platforms. , 2015, Biochimica et biophysica acta.

[26]  Malcolm Anderson,et al.  Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. , 2015, Journal of medicinal chemistry.

[27]  Neal Rosen,et al.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism , 2016, Science.

[28]  Martyn D Winn,et al.  Macromolecular TLS refinement in REFMAC at moderate resolutions. , 2003, Methods in enzymology.

[29]  B. Pentelute,et al.  Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen , 2014, Chembiochem : a European journal of chemical biology.

[30]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[31]  Marc Therrien,et al.  Inhibition of RAS function through targeting an allosteric regulatory site. , 2017, Nature chemical biology.

[32]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[33]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[34]  K. Dutta,et al.  A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling , 2016, Cell.

[35]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[36]  R. Weinberg,et al.  Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene , 1982, Nature.

[37]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[38]  A. Wittinghofer,et al.  Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down. , 2016, Cancer cell.

[39]  Andreas Plückthun,et al.  Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries , 2012, Proceedings of the National Academy of Sciences.

[40]  Alfred Wittinghofer,et al.  GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.

[41]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[42]  E. Nishida,et al.  Dynamics of the Ras/ERK MAPK Cascade as Monitored by Fluorescent Probes* , 2006, Journal of Biological Chemistry.